Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The new proposed plan would permit state Medicaid programs and Medicare Part D insurance plans to voluntarily cover GLP-1 drugs, including those from the market leaders Novo Nordisk and Eli Lilly, the report said
Research Applications Lipolysis Mechanism Investigation AOD9604 serves as a research tool for investigating 3-adrenergic-receptor-dependent lipolytic pathways: Hormone-Sensitive Lipase: Examination of HSL activation, phosphorylation status, and lipid droplet association ATGL Regulation: Research on adipose triglyceride lipase expression and activity modulation Perilipin Phosphorylation: Investigation of lipid droplet coating protein regulation 3-Adrenergic Receptor Dependence: Studies indicating AOD9604s lipolytic effect requires functional 3-adrenergic receptors (abolished in 3-AR knockout models) and is associated with increased 3-AR expression Signaling Cascades: Examination of kinase cascades, calcium signaling, and downstream effectors Research protocols investigate how AOD9604 stimulates lipolysis through mechanisms distinct from catecholamines, providing insights into alternative fat mobilization pathways
The function of PPAR/AMPK/SIRT-1 pathway in inflammatory response of human articular chondrocytes stimulated by advanced glycation end products
Glucagon-like peptide-1 (GLP-1) is a hormone naturally produced in cells of the intestine
These pathway-level effects are proposed based on integrated transcriptomic and protein expression data and warrant further validation
US$ 22.78
US$ 28.89
US$ 21.34
